Investor update
@ HC Andersen Capital

January 4, 2021

bioporto

Forward-Looking Statements

References herein to this presentation shall mean and include this document, any oral presentation accompanying this document provided by BioPorto A/S (the "Company") and any further information that may be made available in connection with the subject matter contained herein. By viewing or receiving or reading this presentation or attending any meeting where this presentation is made, you agree to be bound by the limitations, qualifications and restrictions set out below:

This presentation contains forward-looking statements. Words such as "believe", "expect", "may", "plan", "strategy", "estimate", "target" and similar expressions identify such forward-looking statements. Statements other than historical facts included in this presentation concerning our plans, objectives, goals, future events and performance are forward-looking statements. They involve risks, uncertainties and other factors, which may cause actual results, performance and achievements to differ materially from the results discussed in the forward-looking statements. We undertake no obligation to publicly update or revise forward-looking statements to reflect subsequent events or circumstances after the date of this presentation.

This presentation is confidential, is intended for the recipient only and thus may not be forwarded, reproduced, redistributed or passed to any other person or published in whole or in part for any purpose. If this document has been received in error, it must be returned immediately to the Company. By receiving this presentation, you become bound by the above-referred confidentiality obligation. Failure to comply with such confidentiality obligation may result in civil, administrative or criminal liabilities.

This presentation contains inside information with regard to the Company and/or its securities. Recipients of this presentation should not deal or encourage any other person to deal in the securities of the Company until the transaction described in this Presentation is either announced or abandoned by the Company. Dealing in securities of the Company when in possession of inside information would result in liability for breach of insider dealing restrictions under applicable law, including United States and Danish law.

This presentation is not directed to, or intended for distribution to or use by, any person or entity that is a citizen or resident or located in any locality, state, country or other jurisdiction where such distribution, transmission, publication, availability or use would be contrary to law or regulation or which would require any registration or licensing within such jurisdiction. No communication or information relating to the transaction described herein may be distributed to the public in any jurisdiction in which registration or approval would be required prior to such distribution.

No securities of the Company have been or will be registered under the Securities Act of 1933, as amended (the "Securities Act"), or under any state securities laws, and the securities of the Company may not be offered or sold in the United States (or to, or for the account or benefit of U.S. Persons) except pursuant to an exemption from, or a transaction not subject to, the registration requirements of the Securities Act. The Company does not intend to register in the United States any portion of its securities or to conduct a public offering of any of its securities in the United States. Any offer or sale of the securities of the Company in the United States is limited to "accredited investors" as defined in Rule 501(a), both under the Securities Act. Any securities issued will be "restricted securities" as defined in Rule 144 of the Securities Act.

BioPorto's gRAD

A Development Platform

Highlights gRAD

- Rapid development of lateral flow tests
- High accuracy – same level as the ELISA test
- Multi sample types – plasma, urine, saliva etc.
- Semi-quantitative test result
- Fast test – from sample to result ~10 minutes
- Simple manufacturing process
- Potential use – laboratories, hospitals, out patients
- Low cost

Platform for Product Development & Growth

Leveraging the gRAD platform, BioPorto is developing tests for NGAL as well as three emerging applications:

1. **NGAL:** for near-patient assessment of kidney injury
2. **COVID-19**: a viral diagnostic test
3. **COVID-19:** a serology-based test for immunity assessment (IgG/IgM)
4. **Sepsis**: a blood test using antibodies to thrombomodulin, a marker of endothelial injury, for the early identification of septic shock
5. More to come



Generic Rapid Assay Device (gRAD) platform

BioPorto's patented Generic Rapid Assay Device (gRAD) technology is a lateral flow test development platform with no analyte-specific reagents on the strip.

Instead, labelled capture antibodies and gold nanoparticle conjugated detection antibodies form detectable complexes with the analyte in a simple preanalytical mixing step (off-strip).

Complexes are detected by the dipstick and can be evaluated both qualitatively and quantitatively with superior performance characteristics, compared to standard lateral flow assays.



NGALds for Near-Patient Testing

- NGALds is the first assay developed and approved on the gRAD platform
- CE Mark in Europe on December 30, 2020
- A rapid lateral flow test to offer semi-quantitative urine NGAL results without complexity or instrumentation – ideal for outpatient or low-resource settings
- A sandwich lateral flow immunoassay specific to NGAL, the kit consists of:
  - Lateral flow strips
  - Vials containing lyophilized NGAL antibody
  - Sample dilution buffer
  - Pipette tips

NGALds potential

- High accuracy and high correlation to our lab test The NGAL Test

- Broaden testing for Acute Kidney Injury
    - The NGAL Test: Lab test at Hospitals
    - NGALds: Point of care test at Hospitals (bedside test) and at General Practitioner
    - In the future NGALds can also be used as a home test. This will require a larger usability study

- Enable doctors to treat and help patients sooner

- Excellent screening tool

COVID-19 viral test development process



COVID-19 viral test completed and advanced for clinical testing

- Completion of successful antibody pairing, device prototyping and production agreements
- BioPorto has provided test kits to the University of California, Davis (US) to test samples from approx. 150 COVID-19 patients
- Results are expected in early 2021
- If positive - BioPorto plans to proceed with steps to submit an Emergency Use Authorization (EUA) request to the US Food and Drug Administration (FDA) and a CE mark filing in the EU for the COVID-19 viral test



Financial Calendar 2021

March 17, 2021	Annual report 2020
April 29, 2021	Annual General Meeting
May 12, 2021	Q1 2021 Results
August 18, 2021	Q2 2021 Results
November 17, 2021	Q3 2021 Results

Contact:
Ole Larsen (CFO)
ol@bioporto.com

bioporto